Movicolib

Macrogol 3350, the active ingredient in Movicolib, is an osmotic laxative presented as a powder for oral use. It is used to relieve constipation by retaining water in the intestinal lumen, softening stool and facilitating bowel movements.

GNH USA supplies Movicolib as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Movicolib is an osmotic laxative that acts on the gastrointestinal tract to treat various forms of constipation.

Constipation: softens stool and promotes regular bowel movements. Chronic constipation: provides long‑term relief for patients with persistent constipation. Bowel preparation before colonoscopy: clears the intestinal tract to allow clear visualization during endoscopic procedures.

Movicolib may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Abdominal bloating or distension. - Nausea or mild stomach discomfort. - Flatulence or gas. - Diarrhoea, especially with higher doses. - Thirst or increased fluid intake. - Electrolyte imbalance (mild).

Serious or Rare Side Effects: - Severe dehydration. - Significant electrolyte disturbances (e.g., hypernatremia, hypokalemia). - Allergic reactions such as rash, itching, or swelling. - Persistent abdominal pain. - Signs of intestinal obstruction. - Unexplained weight loss.

Before using Movicolib, consider the following safety measures.

Renal impairment: monitor kidney function and fluid balance. Electrolyte disorders: assess serum electrolytes, especially potassium and sodium. Pregnancy and lactation: use only if clearly needed and prescribed. Elderly patients: start with the lowest effective dose and watch for dehydration. Concurrent laxative use: avoid combining with other osmotic or stimulant laxatives. Store at ambient temperature: keep in the original packaging, protect from moisture and direct sunlight.

Movicolib can interact with other medicines, altering their absorption or electrolyte balance.

Major Interactions (Avoid): - Lithium: increased risk of lithium toxicity due to altered renal clearance. - Digoxin: potential for electrolyte shifts that may affect cardiac conduction. - Certain antibiotics (e.g., quinolones): reduced absorption when taken simultaneously.

Moderate Interactions (Monitor Closely): - Diuretics: monitor for additive effects on fluid and electrolyte status. - Antacids containing magnesium or aluminum: may affect stool consistency. - Antihypertensives: watch for changes in blood pressure due to fluid shifts.